Package Leaflet: Information for the Patient
Calquence 100 mg Film-Coated Tabletsacalabrutinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet:
What is Calquence
What Calquence is used for
Calquence is used to treat adults with chronic lymphocytic leukaemia (CLL).
CLL is a cancer of the white blood cells in the blood called B lymphocytes (or B cells). These cells are part of the immune system (the body's defences).
Calquence is used to treat adults with mantle cell lymphoma (MCL).
MCL is a type of blood cancer that affects the lymph nodes.
How Calquence works
Calquence works by blocking BTK, a protein in the body that helps these cancer cells to grow and survive. By blocking BTK, Calquence helps to kill and may reduce the number of cancer cells, which can slow down the worsening of the disease.
If you have any questions about how Calquence works or why you have been prescribed this medicine, ask your doctor, pharmacist, or nurse.
Do not take Calquence:
If you are not sure, consult your doctor, pharmacist, or nurse before taking Calquence.
Warnings and precautions
Tell your doctor, pharmacist, or nurse before taking Calquence if you:
Tell your doctor if you develop a new lesion or any change in the appearance of a skin area, as you have a high risk of developing skin cancer, see section 4. Use sun protection and have regular skin exams.
During treatment, your doctor will do blood tests to check your blood cell count when necessary.
Children and adolescents
Do not give this medicine to children or adolescents under 18 years old. This is because it has not been studied in this age group.
Other medicines and Calquence
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines, especially:
You can take medicines that reduce stomach acid, such as antacids (calcium carbonate), histamine-2 receptor antagonists (ranitidine and famotidine), and proton pump inhibitors (omeprazole) with Calquence tablets.
Medicines that increase the risk of bleeding
Calquence may make you bleed more easily. Tell your doctor, pharmacist, or nurse if you take other medicines that increase the risk of bleeding:
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. This is because this medicine may harm your unborn baby.
Breast-feeding
Do not breast-feed during treatment with Calquence and for 2 days after receiving the last dose of Calquence. It is not known whether Calquence passes into breast milk.
Driving and using machines
Calquence is unlikely to affect your ability to drive or use machines. However, if you feel dizzy, weak, or tired while taking Calquence, do not drive or use machines.
Calquence contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".
Calquence will only be prescribed by a doctor with experience in using medicines for cancer. Follow your doctor's instructions for taking Calquence exactly. If you are unsure, ask your doctor, pharmacist, or nurse again.
Depending on the type of cancer you have, Calquence may be given in combination with other cancer medicines.
How much to take
How to take Calquence
If you take more Calquence than you should
If you have taken more Calquence than you should, talk to a doctor or go to the nearest hospital immediately. Take the tablets and this leaflet with you.
If you forget to take Calquence
If you have any other questions about using this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Calquence and contact your doctor or go to hospital immediately if you notice any of the following side effects:
Very common serious side effects(may affect more than 1 in 10 people):
Common serious side effects(may affect up to 1 in 10 people):
Other side effects
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Calquence contains
The active substance is acalabrutinib. Each film-coated tablet contains 100 mg of acalabrutinib (as acalabrutinib maleate).
The other ingredients are:
Appearance and packaging of Calquence
Calquence is an orange, 7.5 x 13 mm, oval, biconvex, film-coated tablet engraved with "ACA 100" on one side and plain on the reverse.
Calquence is available in aluminium blisters containing 8 or 10 film-coated tablets. Each blister has sun/moon symbols to help you take your dose at the right time - the sun for the morning dose and the moon for the evening dose. Both sun and moon blisters contain the same medicine. Each carton contains 56 or 60 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
AstraZeneca AB
SE-151 85 Södertälje
Sweden
Manufacturer
AstraZeneca AB
Gärtunavägen
SE-152 57 Södertälje
Sweden
You can get more information about this medicine from your local representative of the marketing authorisation holder:
België/Belgique/Belgien AstraZeneca S.A./N.V. Tel: +32 2 370 48 11 | Lietuva UAB AstraZeneca Lietuva Tel: +370 5 2660550 |
Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11 | |
Ceská republika AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 111 | Magyarország AstraZeneca Kft. Tel: +36 1 883 6500 |
Danmark AstraZeneca A/S Tlf.: +45 43 66 64 62 | Malta Associated Drug Co. Ltd Tel: +356 2277 8000 |
Deutschland AstraZeneca GmbH Tel: +49 40 809034100 | Nederland AstraZeneca BV Tel: +31 85 808 9900 |
Eesti AstraZeneca Tel: +372 6549 600 | Norge AstraZeneca AS Tlf: +47 21 00 64 00 |
Ελλάδα AstraZeneca A.E. Τηλ: +30 210 6871500 | Österreich AstraZeneca Österreich GmbH Tel: +43 1 711 31 0 |
España AstraZeneca Farmacéutica Spain, S.A. Tel: +34 91 301 91 00 | Polska AstraZeneca Pharma Poland Sp. z o.o. Tel: +48 22 245 73 00 |
France AstraZeneca Tél: +33 1 41 29 40 00 | Portugal AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00 |
Hrvatska AstraZeneca d.o.o. Tel: +385 1 4628 000 | România AstraZeneca Pharma SRL Tel: +40 21 317 60 41 |
Ireland AstraZeneca Pharmaceuticals (Ireland) DAC Tel: +353 1609 7100 | Slovenija AstraZeneca UK Limited Tel: +386 1 51 35 600 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika AstraZeneca AB, o.z. Tel: +421 2 5737 7777 |
Italia AstraZeneca S.p.A. Tel: +39 02 00704500 | Suomi/Finland AstraZeneca Oy Puh/Tel: +358 10 23 010 |
Κύπρος Αλ. Ευαγγελίδης Φαρμακευτική Λτδ Τηλ: +357 22490305 | Sverige AstraZeneca AB Tel: +46 8 553 26 000 |
Latvija SIA AstraZeneca Latvija Tel: +371 67377100 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu.